Lonza Launches Capsugel® Zephyr™ - New Dry-Powder Inhalation Capsule Portfolio
- Comprehensive portfolio of high-quality customized Dry-Powder Inhalation (DPI) capsule solutions based on different polymers provides the marketplace with the broad offering of tailor-made solutions to enable consistent and optimal release performance for inhalation products.
- Lonza Pharma & Biotech offers end-to-end inhalation drug delivery development and manufacturing services from particle engineering inclusive of micronization and spray drying, to formulation and encapsulation for use in capsule-based DPI devices.
Basel (CH), 16 May 2019 – Today Lonza announced the launch of Capsugel® Zephyr™, its new dry-powder inhalation (DPI) capsule portfolio, the most complete portfolio of DPI capsules to meet the growing need for customized solutions for optimal pulmonary drug delivery.
Respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are on the rise globally and are among the most life-threatening . Lonza's Capsule Delivery Solutions team developed Capsugel® Zephyr™ capsules as a portfolio of high-quality, highly customizable DPI capsules of different polymers and compositions, and product customization services to help address the specific needs of inhalation drug products manufacturers.
“Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance and is cost-effective to manufacture with various dose carrying capacity. With more than 20 years of experience in manufacturing DPI- capsules, Lonza offers a uniquely customized portfolio of polymers to meet the growing need of inhalation DPI products for pulmonary drug delivery,” stated Stef Vanquickenborne, VP R&D, Lonza Pharma & Biotech.
The Capsugel® Zephyr™ capsule portfolio responds to the marketplace needs for comprehensive inhalation solutions that ensure end-product efficacy with consistent and optimal release performance regardless of formulation characteristics or DPI device principles. With over three billion DPI capsule units delivered worldwide, Lonza offers a full-service inhalation drug-delivery approach based on proven particle engineering platforms, specialized encapsulation technologies as well as customized capsules for use with a large range of DPI devices. The portfolio is further supported by a global integrated supply chain, quality and regulatory support and Lonza's advanced manufacturing network for associated services.
“With the launch of the Capsugel® Zephyr™ capsule portfolio, Lonza will offer full end-to-end solutions for capsule-based DPI products. Our specialized capsule technology provides our customers with the right solution to deliver optimal product performance for the pulmonary route; a testament to how patient-centricity and customer focus are at the heart of Lonza's healthcare continuum,” said Fabio Invernizzi, VP Global Sales, Capsule Delivery Solutions, Lonza Pharma & Biotech.